Loading…

LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma

Cuproptosis is a novel cell death mechanism caused by copper overload, with FDX1 serving as the key regulator. LncRNAs are known to play a significant role in the aberrant regulation of gene expression in hepatocellular carcinoma (HCC). In this study, we investigated the biological role of the LINC0...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cancer research 2023-01, Vol.13 (11), p.5590-5609
Main Authors: Quan, Bing, Liu, Wenfeng, Yao, Fan, Li, Miao, Tang, Bei, Li, Jinghuan, Ren, Zhenggang, Yin, Xin
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 5609
container_issue 11
container_start_page 5590
container_title American journal of cancer research
container_volume 13
creator Quan, Bing
Liu, Wenfeng
Yao, Fan
Li, Miao
Tang, Bei
Li, Jinghuan
Ren, Zhenggang
Yin, Xin
description Cuproptosis is a novel cell death mechanism caused by copper overload, with FDX1 serving as the key regulator. LncRNAs are known to play a significant role in the aberrant regulation of gene expression in hepatocellular carcinoma (HCC). In this study, we investigated the biological role of the LINC02362/hsa-miR-18a-5p/FDX1 axis in HCC. We first explored the expression pattern, prognostic value, biological functions, drug sensitivity, and immune effect of FDX1. Using bioinformatics techniques, we then predicted several potential target lncRNAs and miRNAs. We identified a lncRNA-miRNA-FDX1 axis based on the ceRNA mechanism. In vitro experiments were conducted to validate the relationship between the lncRNA-miRNA-FDX1 axis and its biological effects in HCC. Finally, we investigated the relationship between the LINC02362/hsa-miR-18a-5p/FDX1 axis and oxaliplatin-induced cuproptosis in HCC. Our findings indicated that FDX1 expression was downregulated in HCC tissues; however, elevated FDX1 expression correlates with improved prognosis and heightened sensitivity to oxaliplatin. We confirmed that LINC02362 binds to and directly regulates the expression of miR-18a-5p, with FDX1 a target of miR-18a-5p. Experimental results suggested that upregulating LINC02362/hsa-miR-18a-5p/FDX1 axis suppressed the proliferation of HCC cells. Furthermore, LINC02362 knockdown led to a reduction in copper concentration and resistance to elesclomol-Cu. We also discovered that augmenting the LINC02362/hsa-miR-18a-5p/FDX1 axis could bolster the sensitivity of HCC to oxaliplatin through cuproptosis. This work presents the LINC02362/hsa-miR-18a-5p/FDX1 axis as a novel pathway that triggers cuproptosis and enhances the sensitivity of HCC to oxaliplatin, presenting a promising therapeutic avenue to combat oxaliplatin resistance in HCC.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10695789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2899373228</sourcerecordid><originalsourceid>FETCH-LOGICAL-p197t-d2991ce1f6bfd4009387026754b50c0820495b5cc28920d61b579b4b7461013</originalsourceid><addsrcrecordid>eNpVkNFKwzAUhosobsy9guTSm7IkbdLkSmQ6HQwF9cK7kqapi6RJTNqxvYJPbYdT5rk5h_P_fD_nnCRjjAhNKS_o6dE8SqYxfsChcoh4zs-TUcYgYQyTcfK1Wj7OIc4onq2jSFv9nCImUuJni9s3BMRWRxB774OKUUXggzO6UUF02lkgbA3qoDeDIPtB8p2Lg3-_dlthtDeDz4KobNSd3uhuB1wD1sqLzkllTG9EAFIEqa1rxUVy1ggT1fTQJ8nL4u51_pCunu6X85tV6hEvurTGnCOpUEOrps4h5BkrIKYFySsCJWQY5pxURErMOIY1RRUpeJVXRU4RRNkkuf6h-r5qVS2V7YIwpQ-6FWFXOqHL_4rV6_LdbUoEKScF4wPh6kAI7rNXsStbHffnCKtcH8shl2dFhjEbrJfHYX8pv__PvgFpPITz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2899373228</pqid></control><display><type>article</type><title>LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma</title><source>PubMed Central</source><creator>Quan, Bing ; Liu, Wenfeng ; Yao, Fan ; Li, Miao ; Tang, Bei ; Li, Jinghuan ; Ren, Zhenggang ; Yin, Xin</creator><creatorcontrib>Quan, Bing ; Liu, Wenfeng ; Yao, Fan ; Li, Miao ; Tang, Bei ; Li, Jinghuan ; Ren, Zhenggang ; Yin, Xin</creatorcontrib><description>Cuproptosis is a novel cell death mechanism caused by copper overload, with FDX1 serving as the key regulator. LncRNAs are known to play a significant role in the aberrant regulation of gene expression in hepatocellular carcinoma (HCC). In this study, we investigated the biological role of the LINC02362/hsa-miR-18a-5p/FDX1 axis in HCC. We first explored the expression pattern, prognostic value, biological functions, drug sensitivity, and immune effect of FDX1. Using bioinformatics techniques, we then predicted several potential target lncRNAs and miRNAs. We identified a lncRNA-miRNA-FDX1 axis based on the ceRNA mechanism. In vitro experiments were conducted to validate the relationship between the lncRNA-miRNA-FDX1 axis and its biological effects in HCC. Finally, we investigated the relationship between the LINC02362/hsa-miR-18a-5p/FDX1 axis and oxaliplatin-induced cuproptosis in HCC. Our findings indicated that FDX1 expression was downregulated in HCC tissues; however, elevated FDX1 expression correlates with improved prognosis and heightened sensitivity to oxaliplatin. We confirmed that LINC02362 binds to and directly regulates the expression of miR-18a-5p, with FDX1 a target of miR-18a-5p. Experimental results suggested that upregulating LINC02362/hsa-miR-18a-5p/FDX1 axis suppressed the proliferation of HCC cells. Furthermore, LINC02362 knockdown led to a reduction in copper concentration and resistance to elesclomol-Cu. We also discovered that augmenting the LINC02362/hsa-miR-18a-5p/FDX1 axis could bolster the sensitivity of HCC to oxaliplatin through cuproptosis. This work presents the LINC02362/hsa-miR-18a-5p/FDX1 axis as a novel pathway that triggers cuproptosis and enhances the sensitivity of HCC to oxaliplatin, presenting a promising therapeutic avenue to combat oxaliplatin resistance in HCC.</description><identifier>ISSN: 2156-6976</identifier><identifier>EISSN: 2156-6976</identifier><identifier>PMID: 38058825</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Original</subject><ispartof>American journal of cancer research, 2023-01, Vol.13 (11), p.5590-5609</ispartof><rights>AJCR Copyright © 2023.</rights><rights>AJCR Copyright © 2023 2023</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695789/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695789/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38058825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Quan, Bing</creatorcontrib><creatorcontrib>Liu, Wenfeng</creatorcontrib><creatorcontrib>Yao, Fan</creatorcontrib><creatorcontrib>Li, Miao</creatorcontrib><creatorcontrib>Tang, Bei</creatorcontrib><creatorcontrib>Li, Jinghuan</creatorcontrib><creatorcontrib>Ren, Zhenggang</creatorcontrib><creatorcontrib>Yin, Xin</creatorcontrib><title>LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma</title><title>American journal of cancer research</title><addtitle>Am J Cancer Res</addtitle><description>Cuproptosis is a novel cell death mechanism caused by copper overload, with FDX1 serving as the key regulator. LncRNAs are known to play a significant role in the aberrant regulation of gene expression in hepatocellular carcinoma (HCC). In this study, we investigated the biological role of the LINC02362/hsa-miR-18a-5p/FDX1 axis in HCC. We first explored the expression pattern, prognostic value, biological functions, drug sensitivity, and immune effect of FDX1. Using bioinformatics techniques, we then predicted several potential target lncRNAs and miRNAs. We identified a lncRNA-miRNA-FDX1 axis based on the ceRNA mechanism. In vitro experiments were conducted to validate the relationship between the lncRNA-miRNA-FDX1 axis and its biological effects in HCC. Finally, we investigated the relationship between the LINC02362/hsa-miR-18a-5p/FDX1 axis and oxaliplatin-induced cuproptosis in HCC. Our findings indicated that FDX1 expression was downregulated in HCC tissues; however, elevated FDX1 expression correlates with improved prognosis and heightened sensitivity to oxaliplatin. We confirmed that LINC02362 binds to and directly regulates the expression of miR-18a-5p, with FDX1 a target of miR-18a-5p. Experimental results suggested that upregulating LINC02362/hsa-miR-18a-5p/FDX1 axis suppressed the proliferation of HCC cells. Furthermore, LINC02362 knockdown led to a reduction in copper concentration and resistance to elesclomol-Cu. We also discovered that augmenting the LINC02362/hsa-miR-18a-5p/FDX1 axis could bolster the sensitivity of HCC to oxaliplatin through cuproptosis. This work presents the LINC02362/hsa-miR-18a-5p/FDX1 axis as a novel pathway that triggers cuproptosis and enhances the sensitivity of HCC to oxaliplatin, presenting a promising therapeutic avenue to combat oxaliplatin resistance in HCC.</description><subject>Original</subject><issn>2156-6976</issn><issn>2156-6976</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkNFKwzAUhosobsy9guTSm7IkbdLkSmQ6HQwF9cK7kqapi6RJTNqxvYJPbYdT5rk5h_P_fD_nnCRjjAhNKS_o6dE8SqYxfsChcoh4zs-TUcYgYQyTcfK1Wj7OIc4onq2jSFv9nCImUuJni9s3BMRWRxB774OKUUXggzO6UUF02lkgbA3qoDeDIPtB8p2Lg3-_dlthtDeDz4KobNSd3uhuB1wD1sqLzkllTG9EAFIEqa1rxUVy1ggT1fTQJ8nL4u51_pCunu6X85tV6hEvurTGnCOpUEOrps4h5BkrIKYFySsCJWQY5pxURErMOIY1RRUpeJVXRU4RRNkkuf6h-r5qVS2V7YIwpQ-6FWFXOqHL_4rV6_LdbUoEKScF4wPh6kAI7rNXsStbHffnCKtcH8shl2dFhjEbrJfHYX8pv__PvgFpPITz</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Quan, Bing</creator><creator>Liu, Wenfeng</creator><creator>Yao, Fan</creator><creator>Li, Miao</creator><creator>Tang, Bei</creator><creator>Li, Jinghuan</creator><creator>Ren, Zhenggang</creator><creator>Yin, Xin</creator><general>e-Century Publishing Corporation</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma</title><author>Quan, Bing ; Liu, Wenfeng ; Yao, Fan ; Li, Miao ; Tang, Bei ; Li, Jinghuan ; Ren, Zhenggang ; Yin, Xin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p197t-d2991ce1f6bfd4009387026754b50c0820495b5cc28920d61b579b4b7461013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Quan, Bing</creatorcontrib><creatorcontrib>Liu, Wenfeng</creatorcontrib><creatorcontrib>Yao, Fan</creatorcontrib><creatorcontrib>Li, Miao</creatorcontrib><creatorcontrib>Tang, Bei</creatorcontrib><creatorcontrib>Li, Jinghuan</creatorcontrib><creatorcontrib>Ren, Zhenggang</creatorcontrib><creatorcontrib>Yin, Xin</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Quan, Bing</au><au>Liu, Wenfeng</au><au>Yao, Fan</au><au>Li, Miao</au><au>Tang, Bei</au><au>Li, Jinghuan</au><au>Ren, Zhenggang</au><au>Yin, Xin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma</atitle><jtitle>American journal of cancer research</jtitle><addtitle>Am J Cancer Res</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>13</volume><issue>11</issue><spage>5590</spage><epage>5609</epage><pages>5590-5609</pages><issn>2156-6976</issn><eissn>2156-6976</eissn><abstract>Cuproptosis is a novel cell death mechanism caused by copper overload, with FDX1 serving as the key regulator. LncRNAs are known to play a significant role in the aberrant regulation of gene expression in hepatocellular carcinoma (HCC). In this study, we investigated the biological role of the LINC02362/hsa-miR-18a-5p/FDX1 axis in HCC. We first explored the expression pattern, prognostic value, biological functions, drug sensitivity, and immune effect of FDX1. Using bioinformatics techniques, we then predicted several potential target lncRNAs and miRNAs. We identified a lncRNA-miRNA-FDX1 axis based on the ceRNA mechanism. In vitro experiments were conducted to validate the relationship between the lncRNA-miRNA-FDX1 axis and its biological effects in HCC. Finally, we investigated the relationship between the LINC02362/hsa-miR-18a-5p/FDX1 axis and oxaliplatin-induced cuproptosis in HCC. Our findings indicated that FDX1 expression was downregulated in HCC tissues; however, elevated FDX1 expression correlates with improved prognosis and heightened sensitivity to oxaliplatin. We confirmed that LINC02362 binds to and directly regulates the expression of miR-18a-5p, with FDX1 a target of miR-18a-5p. Experimental results suggested that upregulating LINC02362/hsa-miR-18a-5p/FDX1 axis suppressed the proliferation of HCC cells. Furthermore, LINC02362 knockdown led to a reduction in copper concentration and resistance to elesclomol-Cu. We also discovered that augmenting the LINC02362/hsa-miR-18a-5p/FDX1 axis could bolster the sensitivity of HCC to oxaliplatin through cuproptosis. This work presents the LINC02362/hsa-miR-18a-5p/FDX1 axis as a novel pathway that triggers cuproptosis and enhances the sensitivity of HCC to oxaliplatin, presenting a promising therapeutic avenue to combat oxaliplatin resistance in HCC.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>38058825</pmid><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2156-6976
ispartof American journal of cancer research, 2023-01, Vol.13 (11), p.5590-5609
issn 2156-6976
2156-6976
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10695789
source PubMed Central
subjects Original
title LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T05%3A49%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LINC02362/hsa-miR-18a-5p/FDX1%20axis%20suppresses%20proliferation%20and%20drives%20cuproptosis%20and%20oxaliplatin%20sensitivity%20of%20hepatocellular%20carcinoma&rft.jtitle=American%20journal%20of%20cancer%20research&rft.au=Quan,%20Bing&rft.date=2023-01-01&rft.volume=13&rft.issue=11&rft.spage=5590&rft.epage=5609&rft.pages=5590-5609&rft.issn=2156-6976&rft.eissn=2156-6976&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2899373228%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p197t-d2991ce1f6bfd4009387026754b50c0820495b5cc28920d61b579b4b7461013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2899373228&rft_id=info:pmid/38058825&rfr_iscdi=true